Company
Headquarters: Hayward, CA, United States
Employees: 95
CEO: Mr. Darrin R. Uecker
$1.10 Billion
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Intuitive | $216.79 B |
EssilorLuxottica SA | $116.96 B |
Becton, Dickinson and Company | $69.74 B |
HOYA Corp | $45.26 B |
Alcon Inc. | $41.55 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Last Financial Reports Date | Dec. 31, 2023 |
Revenue TTM | $0 |
EBITDA | $-42,370,000 |
Gross Profit TTM | $0 |
Profit Margin | 0.00% |
Operating Margin | 0.00% |
Quarterly Revenue Growth | % |
Pulse Biosciences, Inc. has the following listings and related stock indices.
Stock: NASDAQ: PLSE wb_incandescent
Stock: FSX: 6L8 wb_incandescent